平特五不中

The EDDU got a lot done in 2023, holding its third virtual iPSC training workshop in partnership with Stem Cell technologies, as well as 6 iPSC seminars with experts from around the world presenting their latest finding. On our end, we helped to publish 12 open-access papers with 7 more pre-prints online and in review, along with a new open-access protocol, and a number of new posters presented at conferences throughout the year. In November we attended the Canadian Network of Scientific Platforms Meeting and rounded out the year attending the鈥疉LS/MND symposium in Switzerland!

The EDDU also formed key partnerships, joining the TRIDENT initiative thanks to $24 million over seven years in new funding through The New Frontiers in Research Fund (). Our Director of Thomas Durcan, a鈥痗o-PI on the project, leads the iPSC testing platform, and working with teams from Western, U. of Toronto and UBC towards identifying therapeutics for neurodegenerative diseases. 鈥疧ther new partnerships included the G-CAN initiative (/neuro/article/research/neurodegenerative-gene-focu...), thanks in part to funding from the Weston foundation and Van Berkom foundation, with the EDDU members helping to generate new mutant GBA iPSCs and developing new assays and therapeutics towards targeting GBA in Parkinson鈥檚. With these partnerships, the EDDU goes from strength to strength, and during 2023 we looked beyond our current space, setting up a strategic partnership with IRCM, in which we have now established a new satellite site dedicated to IRCM and EDDU stem cell focused projects. More to come in 2024.

We also have to congratulate Carol Chen, a senior member of the EDDU and manager of our IPSC colonies who, was awarded one of the 2023 Champion Award for Research Staff at the Neuro for her efforts in Open Science research.

So all in all, lots of work, some fun times as a team and a renewed focus for the year ahead.

2022 started well with Thomas Durcan becoming the new Director of the EDDU. Also, at the beginning of the year we held our second virtual iPSC training workshop in partnership with Stem Cell technologies, with great success.

In 2022, we continued to build fruitful partnerships and we are grateful for the generous support we have received from The Neuro鈥檚 TOSI Grassroots Initiative. With this support, we grew our outreach and training videos portfolio with seven new , two new , and all our training videos now translated to Spanish and Portuguese.

We also received funding from the to develop an 鈥淎utomated 3D brain organoid imaging platform鈥� for discovery and translational activities.听

Over the course of the year, we hosted five iPSC seminars, with four of which were virtual, and one being our first in-person seminar in nearly three years. With the return of in-person conferences, we were able to attend the SfN2022 in San Diego! We also published , and two updated open-access protocols.听

This year, we also said goodbye to some dear lab members, and also welcomed new members to our team.

With the lab now back open, the EDDU embraced the hybrid in person-virtual life of a scientist with the iPSC seminar series continuing in a virtual manner growing to over 80 attendees for each meeting. We held our first virtual in partnership with Stem Cell technologies, published six , one book chapter and one new open-access SOP.听

Underlining all the new initiatives and work coming from the EDDU, we launched an updated version of the website, with a new with open science video protocols for anyone, anywhere in the world to be able to work with iPSCs in the same manner as we do. With versions in English and French now available, new languages are in development and will be coming online in the coming months as our virtual offerings increase.听

With new funding, new personnel and new projects coming online or nearing completion, this has been a year of significant growth as the EDDU builds towards the future and next decade.

Like many other labs, on March 19th 2020 the EDDU lab was shut down with everyone working from home. While staying apart, the group stayed together through all virtual means possible and on May 25th, after being closed for 3 months, we reopened the lab. Over the next 6 months, team members started returning in a phased manner. New protocols were implemented, lab work was restarted and, by the end of the year, projects were brought to a natural conclusion and new ones had been started. Through the extended time at home, the team put our hands and brains together to write. The EDDU麓s team published nine and three .

The EDDU held its second iPSC training workshop, published 2 open-access review articles (bringing their total to 3), and launched a blog on to share protocols and expertise. The iPSC/CRISPR Platform is now known as The Neuro's Early Drug Discovery Unit (EDDU) to encompass all the activities that are part of the group.

The work of the iPSC/CRISPR Platform is featured on The Neuro's Neuro XXceptional series and in the media, with coverage from , , and .

The EDDU held its second iPSC training workshop, published 2 open-access review articles (bringing their total to 3), and launched a blog on to share protocols and expertise.

New industry partnerships and philanthropic gifts to The Neuro allow the iPSC/CRISPR Platform to expand its research focus to ALS and intellectual disabilities.

The iPSC/CRISPR Platform is launched at The Neuro with an initial focus on Parkinson鈥檚 disease, thanks to a generous $1 million gift from Mr. J. Sebastian van Berkom, and partnerships with , , and the .